Literature DB >> 32453840

Myeloma cells induce the accumulation of activated CD94low NK cells by cell-to-cell contacts involving CD56 molecules.

Chiara Barberi1,2, Claudia De Pasquale3, Alessandro Allegra4, Giacomo Sidoti Migliore1,2, Daniela Oliveri5, Fabrizio Loiacono6, Vanessa Innao4, Caterina Musolino4, Daniela Pende6, Claudia Cantoni1,2,7, Paolo Carrega3, Maria Cristina Mingari1,2,6, Stefania Campana3, Guido Ferlazzo3,5.   

Abstract

Natural killer (NK) cells represent innate effector cells potentially able to play a role during the immune response against multiple myeloma (MM). To better define the distribution and the specific properties of NK cell subsets during MM disease, we analyzed their features in the bone marrow and peripheral blood of newly diagnosed MM patients. Our findings revealed that, in both compartments, NK cells were more abundant than in healthy donors. Among total MM-NK cells, a significant increase of CD94lowCD56dim NK cell subset was observed, which already appears in clinical precursor conditions leading to MM, namely monoclonal gammopathy of undetermined significance and smoldering MM, and eventually accumulates with disease progression. Moreover, a consistent fraction of CD94lowCD56dim NK cells was in a proliferation phase. When analyzed for their killing abilities, they represented the main cytotoxic NK cell subset against autologous MM cells. In vitro, MM cells could rapidly induce the expansion of the CD94lowCD56dim NK cell subset, thus reminiscent of that observed in MM patients. Mechanistically, this accumulation relied on cell to cell contacts between MM and NK cells and required both activation via DNAM-1 and homophilic interaction with CD56 expressed on MM cells. Considering the growing variety of combination treatments aimed at enhancing NK cell-mediated cytotoxicity against MM, these results may also be informative for optimizing current immunotherapeutic approaches.
© 2020 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2020        PMID: 32453840      PMCID: PMC7252548          DOI: 10.1182/bloodadvances.2019000953

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  31 in total

1.  CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset.

Authors:  Sandra Lopez-Vergès; Jeffrey M Milush; Suchitra Pandey; Vanessa A York; Janice Arakawa-Hoyt; Hanspeter Pircher; Philip J Norris; Douglas F Nixon; Lewis L Lanier
Journal:  Blood       Date:  2010-08-23       Impact factor: 22.113

2.  Dissecting CD56dim human NK cells.

Authors:  Lorenzo Moretta
Journal:  Blood       Date:  2010-11-11       Impact factor: 22.113

Review 3.  From myeloma precursor disease to multiple myeloma: new diagnostic concepts and opportunities for early intervention.

Authors:  Ola Landgren; Robert A Kyle; S Vincent Rajkumar
Journal:  Clin Cancer Res       Date:  2011-03-15       Impact factor: 12.531

4.  CD56(bright)perforin(low) noncytotoxic human NK cells are abundant in both healthy and neoplastic solid tissues and recirculate to secondary lymphoid organs via afferent lymph.

Authors:  Paolo Carrega; Irene Bonaccorsi; Emma Di Carlo; Barbara Morandi; Petra Paul; Valeria Rizzello; Giuseppe Cipollone; Giuseppe Navarra; Maria Cristina Mingari; Lorenzo Moretta; Guido Ferlazzo
Journal:  J Immunol       Date:  2014-03-19       Impact factor: 5.422

5.  HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells.

Authors:  Ennio Carbone; Paola Neri; Maria Mesuraca; Mariateresa T Fulciniti; Takemi Otsuki; Daniela Pende; Veronika Groh; Thomas Spies; Giuditta Pollio; David Cosman; Lucio Catalano; Pierfrancesco Tassone; Bruno Rotoli; Salvatore Venuta
Journal:  Blood       Date:  2004-08-24       Impact factor: 22.113

6.  CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK-cell subsets.

Authors:  Jianhua Yu; Hsiaoyin C Mao; Min Wei; Tiffany Hughes; Jianying Zhang; Il-kyoo Park; Shujun Liu; Susan McClory; Guido Marcucci; Rossana Trotta; Michael A Caligiuri
Journal:  Blood       Date:  2009-11-06       Impact factor: 22.113

7.  Analysis of the KIR repertoire in human NK cells by flow cytometry.

Authors:  Niklas K Björkström; Cyril Fauriat; Yenan T Bryceson; Johan K Sandberg; Hans-Gustaf Ljunggren; Karl-Johan Malmberg
Journal:  Methods Mol Biol       Date:  2010

8.  Identity of Leu-19 (CD56) leukocyte differentiation antigen and neural cell adhesion molecule.

Authors:  L L Lanier; R Testi; J Bindl; J H Phillips
Journal:  J Exp Med       Date:  1989-06-01       Impact factor: 14.307

Review 9.  CD56 in the Immune System: More Than a Marker for Cytotoxicity?

Authors:  Heleen H Van Acker; Anna Capsomidis; Evelien L Smits; Viggo F Van Tendeloo
Journal:  Front Immunol       Date:  2017-07-24       Impact factor: 7.561

10.  Key Role of the CD56lowCD16low Natural Killer Cell Subset in the Recognition and Killing of Multiple Myeloma Cells.

Authors:  Elisabetta Vulpis; Helena Stabile; Alessandra Soriani; Cinzia Fionda; Maria Teresa Petrucci; Elena Mariggio'; Maria Rosaria Ricciardi; Marco Cippitelli; Angela Gismondi; Angela Santoni; Alessandra Zingoni
Journal:  Cancers (Basel)       Date:  2018-11-29       Impact factor: 6.639

View more
  8 in total

Review 1.  Harnessing Unconventional T Cells and Innate Lymphoid Cells to Prevent and Treat Hematological Malignancies: Prospects for New Immunotherapy.

Authors:  Alessandro Allegra; Marco Casciaro; Elena Lo Presti; Caterina Musolino; Sebastiano Gangemi
Journal:  Biomolecules       Date:  2022-05-27

Review 2.  New Frontiers about the Role of Human Microbiota in Immunotherapy: The Immune Checkpoint Inhibitors and CAR T-Cell Therapy Era.

Authors:  Vanessa Innao; Andrea Gaetano Allegra; Caterina Musolino; Alessandro Allegra
Journal:  Int J Mol Sci       Date:  2020-11-24       Impact factor: 5.923

Review 3.  Targeting NK Cell Inhibitory Receptors for Precision Multiple Myeloma Immunotherapy.

Authors:  Helmi Alfarra; Jackson Weir; Stacy Grieve; Tony Reiman
Journal:  Front Immunol       Date:  2020-11-12       Impact factor: 7.561

Review 4.  Multiple Myeloma Cell-Derived Exosomes: Implications on Tumorigenesis, Diagnosis, Prognosis and Therapeutic Strategies.

Authors:  Alessandro Allegra; Mario Di Gioacchino; Alessandro Tonacci; Claudia Petrarca; Caterina Musolino; Sebastiano Gangemi
Journal:  Cells       Date:  2021-10-24       Impact factor: 6.600

Review 5.  Inflammaging, an Imbalanced Immune Response That Needs to Be Restored for Cancer Prevention and Treatment in the Elderly.

Authors:  Juana Serrano-López; Beatriz Martín-Antonio
Journal:  Cells       Date:  2021-09-28       Impact factor: 6.600

6.  Single-cell transcriptome profiling reveals the key role of ZNF683 in natural killer cell exhaustion in multiple myeloma.

Authors:  Xin Li; Mengping Chen; Yike Wan; Lu Zhong; Xiaofeng Han; Xiaotong Chen; Fei Xiao; Jia Liu; Yiwei Zhang; Di Zhu; Jing Xiang; Junling Liu; Honghui Huang; Jian Hou
Journal:  Clin Transl Med       Date:  2022-10

Review 7.  The Cancer-Immunity Cycle in Multiple Myeloma.

Authors:  Mika Casey; Kyohei Nakamura
Journal:  Immunotargets Ther       Date:  2021-07-16

Review 8.  A Hot Topic: Cancer Immunotherapy and Natural Killer Cells.

Authors:  Tatiana Michel; Markus Ollert; Jacques Zimmer
Journal:  Int J Mol Sci       Date:  2022-01-12       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.